LIFECORE BIOMEDICAL, INC. Financing Receivable, Allowance for Credit Loss, Writeoff, after Recovery
LIFECORE BIOMEDICAL, INC. (LFCR) reported Financing Receivable, Allowance for Credit Loss, Writeoff, after Recovery of $607.00 thousand for the 9-month period ending 2021-02-28, per its 10-Q filed 2021-04-08.
Discontinued › Notes › Credit Losses
us-gaap:FinancingReceivableAllowanceForCreditLossWriteoffAfterRecovery · last filed 2021-04-08
- LIFECORE BIOMEDICAL, INC. financing receivable, allowance for credit loss, writeoff, after recovery for the quarter ending 2021-02-28 was $344.00K.
- LIFECORE BIOMEDICAL, INC. financing receivable, allowance for credit loss, writeoff, after recovery for the quarter ending 2020-11-29 was $94.00K.
- LIFECORE BIOMEDICAL, INC. financing receivable, allowance for credit loss, writeoff, after recovery for the quarter ending 2020-08-30 was $169.00K.
| Period end | Financing Receivable, Allowance for Credit Loss, Writeoff, after Recovery 3 month | Financing Receivable, Allowance for Credit Loss, Writeoff, after Recovery 6 month | Financing Receivable, Allowance for Credit Loss, Writeoff, after Recovery 9 month |
|---|---|---|---|
| 2021-02-28 | $344.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-04-08 | $438.00K derived: sum of 2 quarters · filed 2021-04-08 | $607.00K 10-Q · filed 2021-04-08 |
| 2020-11-29 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-01-07 | $263.00K 10-Q · filed 2021-01-07 | |
| 2020-08-30 | $169.00K 10-Q · filed 2020-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |